BURLINGTON, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies

Investors interested in Medical - Products stocks are likely familiar with GE HealthCare Technologie

LeMaitre Vascular remains a Buy after a 31% pullback, though I have trimmed my price target to $95-$

BURLINGTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced

Gainers Zhengye Biotechnology (NASDAQ:ZYBT) stock increased by 107.0% to $2.65 during Wednesday&#39

Wells Fargo analyst Nathan Treybeck maintains LeMaitre Vascular (NASDAQ:LMAT) with a Equal-Weight

LeMaitre Vascular, Inc. (LMAT) Q2 2026 Earnings Call Transcript

LeMaitre Vascular NASDAQ: LMAT reported second-quarter 2026 results marked by 10% organic revenue gr

LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.74 per share, missing the Zacks Cons

Gainers Bluejay Diagnostics (NASDAQ:BJDX) stock moved upwards by 42.0% to $1.42 during Tuesday'

LeMaitre Vascular (NASDAQ:LMAT) is looking for Q4 GAAP EPS of $0.75-$0.81 vs $0.78 analyst estimate.

LeMaitre Vascular (NASDAQ:LMAT) is looking for Q3 GAAP EPS of $0.66-$0.71 vs $0.73 analyst estimate.

LeMaitre Vascular (NASDAQ:LMAT) lowers FY2026 GAAP EPS guidance from $2.93-$3.08 to $2.84-$2.94 vs $

LeMaitre Vascular (NASDAQ:LMAT) reported quarterly earnings of $0.74 per share which missed the anal

BURLINGTON, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provi

BURLINGTON, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced

I don't love valuation models because they rely on assumptions, and assumptions can be dangerous. Bu

CASY, CLS, PNTG and LMAT stand out for strong interest coverage as borrowing costs rise, with solid

LeMaitre (LMAT) possesses solid growth attributes, which could help it handily outperform the market

BURLINGTON, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced

LeMaitre (LMAT) has become technically an oversold stock now, which implies exhaustion of the heavy

BURLINGTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT) announced

LeMaitre (LMAT) is well positioned to outperform the market, as it exhibits above-average growth in

LeMaitre (LMAT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the co

Barrington Research analyst Michael Petusky maintains LeMaitre Vascular (NASDAQ:LMAT) with a Outp

Citizens analyst Daniel Stauder maintains LeMaitre Vascular (NASDAQ:LMAT) with a Market Outperfor

Wells Fargo analyst Nathan Treybeck maintains LeMaitre Vascular (NASDAQ:LMAT) with a Equal-Weight

LeMaitre Vascular, Inc. (LMAT) Q1 2026 Earnings Call Transcript

LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.68 per share, beating the Zacks Cons

LeMaitre Vascular (NASDAQ:LMAT) is looking for Q2 GAAP EPS of $0.79-$0.84 vs $0.75 analyst estimate.

LeMaitre Vascular (NASDAQ:LMAT) raises FY2026 GAAP EPS guidance from $2.81-$3.01 to $2.93-$3.08 vs $

LeMaitre Vascular (NASDAQ:LMAT) reported quarterly earnings of $0.68 per share which beat the analys

Barrington Research analyst Michael Petusky maintains LeMaitre Vascular (NASDAQ:LMAT) with a Outp

Roth Capital analyst Kyle Bauser reiterates LeMaitre Vascular (NASDAQ:LMAT) with a Buy and raises

Wells Fargo analyst Nathan Treybeck maintains LeMaitre Vascular (NASDAQ:LMAT) with a Equal-Weight

Citizens analyst Daniel Stauder maintains LeMaitre Vascular (NASDAQ:LMAT) with a Market Outperfor

LeMaitre Vascular (NASDAQ:LMAT) is looking for FY2026 GAAP EPS of $2.81-$3.01 vs $2.58 analyst estim

LeMaitre Vascular (NASDAQ:LMAT) is looking for Q1 GAAP EPS of $0.64-$0.69 vs $0.61 analyst estimate.

LeMaitre Vascular (NASDAQ:LMAT) reported quarterly earnings of $0.68 per share which beat the analys

Barrington Research analyst Michael Petusky maintains LeMaitre Vascular (NASDAQ:LMAT) with a Outp

Wells Fargo analyst Nathan Treybeck maintains LeMaitre Vascular (NASDAQ:LMAT) with a Equal-Weight